Breaking News From Pharma & Bio Ingredients
Memory Launches PDE10A Inhibitor Program
Posted on 2005-02-23 06:05:00
Memory Pharmaceuticals Corp., Montvale, NJ, has added a PDE10A inhibitor program to its pipeline. The preclinical PDE10A inhibitor program, the fourth program to be added to the Company's pipeline, is based on promising preclinical research suggesting that the inhibition of PDE10A may reduce psychotic effects and may therefore be useful in treating psychiatric disorders such as schizophrenia.
"The PDE10A inhibitor program is a program that we are actively pursuing with our integrated team of biologists, chemists and preclinical development scientists. We believe PDE10A is a compelling target for novel antipsychotics and are pleased to formally announce the addition of this program to our pipeline," said David A. Lowe, Ph.D., chief scientific officer, Memory Pharmaceuticals. "The advancement of this program is consistent with our mission to develop novel treatments for CNS disorders based on our extensive knowledge of and experience with a diverse set of pathways."
PDE10A is a class of phosphodiesterases that degrades cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10A activity, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved. PDE10A has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders such as schizophrenia, Parkinson's disease and obsessive compulsive disorder. PDE10A inhibitors may therefore be useful in treating these disorders.
Subscribe via RSS
